Three more patches for treating menopause will no longer carry black-box warnings about cardiovascular disease, breast cancer and dementia, officials at the US Food and Drug Administration (FDA) said on Friday.
asserted
officials → treat → Friday
The FDA did not convene an advisory committee and offered few details on the scientific basis for the decision in the press briefing.
asserted
FDA → convene → briefing
The news follows the removal of black-box warnings from six menopause treatments in February, as patients across the US struggle with shortages of the patches.
asserted
patients → follow → patches
When journalists asked for the evidence behind this decision, officials said it could be provided later.
uncertain
it → ask → decision
“I have been concerned by the lack of transparency behind these decisions,” said Reshma Ramachandran, an assistant professor and health services researcher at Yale School of Medicine.
asserted
Ramachandran → concern → Medicine
“The blanket removal of black-box warnings regarding risks of breast cancer and cardiovascular disease without clear justification can be misleading for patients and underplays real potential harms.”
There are particular risks for certain groups of patients, such as those with histories of hormone-sensitive cancers, she said.
asserted
she → regard → cancers
Instead, officials highlighted the shortages patients are facing for menopause hormone treatments (MHT).
asserted
patients → highlight → treatments
“We are working with manufacturers to strengthen supply and improve access,” said Dorothy Fink, deputy director of the National Institute of Child Health and Human Development.
asserted
Fink → work → Health
Manufacturing of estrogen patches has doubled over the past year, she said.
asserted
she → double → year
Even so, patients report stock-outs of the patches.
asserted
patients → report → patches
“We know that for some patients, these past months have been frustrating,” said Sarah Ibrahim, deputy center director for regulatory programs of the FDA’s Center for Drug Evaluation and Research.
asserted
Ibrahim → know → Evaluation
After the change to labels in February, demand for estradiol patches “increased significantly, and patients in many areas found it difficult to get their usual patches at their usual pharmacy”, she said.
asserted
she → increase → pharmacy
“And I want you to know that we hear you.”
asserted
we → want → you
The FDA is working with manufacturers to ramp up production, and the agency is also working to change the labels of the remaining MHT products, Ibrahim said.
asserted
Ibrahim → work → products
The black-box warnings “painted a broad and, in some cases, overstated pictures of risk”, she said.
asserted
she → paint → risk
“Updated evidence shows that for many healthy women under 60 and within 10 years of menopause onset, the risk-benefit profile looks meaningfully different than older warnings conveyed.”
asserted
profile → update → warnings
Estradiol patches are usually considered lower risk than synthetic oral medications, because they pass into the bloodstream without first going to the liver.
asserted
they → consider → liver
The risks of the patches are higher with high doses, research shows.
asserted
research → show → doses
Officials in the Trump administration have made sweeping and “data-free” claims about the benefits of MHT, including improvements in longevity, which are not supported by research, menopause experts have said.
uncertain
experts → make → research
While there are benefits to the treatments for some women, the decision not to convene advisers or include research
asserted
decision → be → research
sets a troubling precedent, they said.
asserted
they → set → precedent
The FDA bypassed its advisory committees last November in announcing it would remove the warnings; at the time, a spokesperson said that the reason is because committees are “bureaucratic, long, often conflicted, and very expensive”.
asserted
committees → bypass → time
Instead, the FDA convened a panel in July 2025 featuring doctors and influencers, all of whom were vocal proponents of MHT and several of whom had conflicts of interest with practices that market and sell hormone therapy, Ramachandran said.
asserted
Ramachandran → convene → therapy
“At the expert meeting, they also did not allow for public testimony,” Ramachandran said – including from the lead investigator of the Women’s Health Initiative, research from which formed the recommendations for MHT, who was in the audience.
asserted
who → allow → audience
After audience members voiced concern, the FDA opened a docket for public comment.
asserted
FDA → voice → comment
The FDA is also exploring the possibility of offering vaginal estrogen products over the counter, according to an agency press release on Friday.
uncertain
FDA → explore → Friday
The Aporia
